Rapport Therapeutics, Inc. (RAPP) Balance Sheet
RAPP balance sheet, 2025
December 31, 2025 · U.S. dollars$512.4M assets = $27.8M liabilities + $484.7M equity
Both columns are drawn to the same scale: what RAPP owns equals what it owes plus shareholders’ equity. Hover a block for its value.
RAPP financial health
Descriptive bands, not a rating. Fiscal 2025.
RAPP balance sheet trends, 2022–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $31.6M2022 | $512.4M2025 | +153.1%/yr | |
| Total liabilities | $12.1M2022 | $27.8M2025 | +31.9%/yr | |
| Shareholders’ equity | $19.5M2022 | $484.7M2025 | +191.8%/yr | |
| Cash & short-term investments | $31.2M2022 | $490.5M2025 | +150.6%/yr | |
| Total debt | $10.4M2022 | $11.5M2025 | +3.2%/yr | |
| Net cash (debt) | $20.7M2022 | $479.1M2025 | +$458.3M | |
| Working capital | $29.6M2022 | $479.5M2025 | +$449.9M | |
| Book value per share | $0.972022 | $10.322025 | +119.9%/yr | |
| Debt / equity | 0.532022 | 0.022025 | −0.51 | |
| Shares outstanding | 20.1M2022 | 47.0M2025 | +32.7%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
RAPP assets
RAPP liabilities and equity
RAPP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
RAPP balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | $490.5M | $305.3M | $147.5M | $31.2M |
| Cash & equivalents | $52.6M | $56.8M | $70.2M | $31.2M |
| Short-term investments | $437.9M | $248.5M | $77.3M | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other current assets | $8.0M | $4.5M | $3.4M | $109,000 |
| Total current assets | $498.6M | $309.8M | $150.9M | $31.3M |
| Property, plant & equipment (net) | $12.9M | $5.0M | $4.0M | $335,000 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 |
| Other non-current assets | $985,000 | $160,000 | $551,000 | $0 |
| Total assets | $512.4M | $314.9M | $155.4M | $31.6M |
| Liabilities | ||||
| Accounts payable | $4.2M | $2.0M | $2.5M | $1.4M |
| Short-term debt | $2.8M | $737,000 | $670,000 | — |
| Deferred revenue | — | — | −$2.5M | — |
| Total current liabilities | $19.0M | $8.8M | $8.8M | $1.7M |
| Long-term debt | $0 | $0 | $0 | $0 |
| Lease obligations | $11.5M | $1.5M | $2.1M | $0 |
| Other long-term liabilities | $8.7M | $739,000 | $172.3M | $10.4M |
| Total liabilities | $27.8M | $9.5M | $181.1M | $12.1M |
| Shareholders' equity | ||||
| Common stock & paid-in capital | $48,000 | $37,000 | $4,000 | $31,000 |
| Retained earnings (deficit) | −$235.2M | −$123.7M | −$45.4M | −$10.7M |
| Accumulated other comprehensive income | $546,000 | −$522,000 | $4,000 | −$31,000 |
| Total shareholders' equity | $484.7M | $305.4M | −$25.6M | $19.5M |
| Key figures | ||||
| Total debt | $11.5M | $1.5M | $2.1M | $10.4M |
| Net cash (debt) | $479.1M | $303.8M | $145.3M | $20.7M |
| Working capital | $479.5M | $301.0M | $142.1M | $29.6M |
| Tangible book value | $484.7M | $305.4M | −$25.6M | $19.5M |
| Book value per share | $10.32 | $14.73 | −$1.42 | $0.97 |
| Shares outstanding | 47.0M | 20.7M | 18.1M | 20.1M |
| Current ratio | 26.17 | 35.34 | 17.14 | 18.80 |
| Quick ratio | 25.75 | 34.82 | 16.75 | 18.74 |
| Debt / equity | 0.02 | 0.00 | — | 0.53 |
| Equity / assets | 94.6% | 97.0% | −16.5% | 61.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & short-term investments | $436.1M | $476.8M | $490.5M | $513.0M | $260.4M | $285.4M | $305.3M | $320.7M | $336.1M | $193.2M | $147.5M |
| Cash & equivalents | $63.6M | $78.1M | $52.6M | $251.4M | $55.1M | $57.6M | $56.8M | $39.3M | $110.2M | $74.3M | $70.2M |
| Short-term investments | $372.5M | $398.7M | $437.9M | $261.7M | $205.4M | $227.8M | $248.5M | $281.3M | $226.0M | $119.0M | $77.3M |
| Receivables | $293,000 | $58,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $10.5M | $7.9M | $8.0M | $7.6M | $9.8M | $5.6M | $4.5M | $5.3M | $4.5M | $5.5M | $3.4M |
| Total current assets | $446.9M | $484.7M | $498.6M | $520.7M | $270.2M | $291.0M | $309.8M | $325.9M | $340.7M | $198.7M | $150.9M |
| Property, plant & equipment (net) | $11.1M | $11.8M | $12.9M | $13.6M | $14.2M | $10.9M | $5.0M | $5.0M | $5.2M | $5.5M | $4.0M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1.1M | $1.1M | $985,000 | $1.1M | $1.0M | $211,000 | $160,000 | $189,000 | $189,000 | $2.1M | $551,000 |
| Total assets | $459.0M | $497.6M | $512.4M | $535.3M | $285.5M | $302.1M | $314.9M | $331.1M | $346.1M | $206.3M | $155.4M |
| Liabilities | |||||||||||
| Accounts payable | $2.8M | $6.6M | $4.2M | $3.2M | $3.2M | $2.1M | $2.0M | $1.3M | $1.9M | $1.4M | $2.5M |
| Short-term debt | $2.5M | $2.6M | $2.8M | $2.5M | $1.8M | $1.0M | $737,000 | $720,000 | $703,000 | $686,000 | $670,000 |
| Deferred revenue | — | — | — | — | — | — | — | — | −$1.9M | −$1.4M | — |
| Total current liabilities | $28.4M | $17.9M | $19.0M | $14.3M | $11.9M | $9.4M | $8.8M | $7.1M | $8.1M | $9.9M | $8.8M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $10.1M | $10.8M | $11.5M | $11.9M | $11.9M | $7.8M | $1.5M | $1.7M | $1.8M | $2.0M | $2.1M |
| Other long-term liabilities | $7.6M | $8.2M | $8.7M | $9.4M | $10.1M | $6.8M | $739,000 | $931,000 | $1.1M | $236.0M | $172.3M |
| Total liabilities | $36.1M | $26.1M | $27.8M | $23.7M | $22.0M | $16.2M | $9.5M | $8.0M | $9.2M | $245.9M | $181.1M |
| Shareholders' equity | |||||||||||
| Common stock & paid-in capital | $48,000 | $48,000 | $48,000 | $48,000 | $37,000 | $37,000 | $37,000 | $36,000 | $36,000 | $4,000 | $4,000 |
| Retained earnings (deficit) | −$311.7M | −$255.1M | −$235.2M | −$201.5M | −$174.5M | −$147.8M | −$123.7M | −$103.8M | −$86.2M | −$68.1M | −$45.4M |
| Accumulated other comprehensive income | −$1.3M | −$505,000 | $546,000 | $145,000 | −$76,000 | −$95,000 | −$522,000 | $400,000 | −$183,000 | −$160,000 | $4,000 |
| Total shareholders' equity | $422.9M | $471.5M | $484.7M | $511.6M | $263.5M | $285.8M | $305.4M | $323.1M | $336.9M | −$39.6M | −$25.6M |
| Key figures | |||||||||||
| Total debt | $10.1M | $10.8M | $11.5M | $11.9M | $11.9M | $7.8M | $1.5M | $1.7M | $1.8M | $2.0M | $2.1M |
| Net cash (debt) | $426.0M | $466.0M | $479.1M | $501.2M | $248.6M | $277.5M | $303.8M | $319.0M | $334.3M | $191.3M | $145.3M |
| Working capital | $418.4M | $466.8M | $479.5M | $506.3M | $258.4M | $281.6M | $301.0M | $318.8M | $332.6M | $188.8M | $142.1M |
| Tangible book value | $422.9M | $471.5M | $484.7M | $511.6M | $263.5M | $285.8M | $305.4M | $323.1M | $336.9M | −$39.6M | −$25.6M |
| Book value per share | $8.91 | $9.98 | $10.32 | $13.49 | $7.43 | $14.82 | $15.83 | $16.85 | $16.75 | −$2.04 | −$1.42 |
| Shares outstanding | 47.5M | 47.2M | 47.0M | 37.9M | 35.4M | 19.3M | 19.3M | 19.2M | 20.1M | 19.5M | 18.1M |
| Current ratio | 15.72 | 27.08 | 26.17 | 36.37 | 22.75 | 31.01 | 35.34 | 45.91 | 42.08 | 20.10 | 17.14 |
| Quick ratio | 15.35 | 26.64 | 25.75 | 35.84 | 21.92 | 30.41 | 34.82 | 45.17 | 41.52 | 19.55 | 16.75 |
| Debt / equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.05 | 0.03 | 0.00 | 0.01 | 0.01 | — | — |
| Equity / assets | 92.1% | 94.8% | 94.6% | 95.6% | 92.3% | 94.6% | 97.0% | 97.6% | 97.3% | −19.2% | −16.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 10, 2026); data from EODHD.
RAPP financial position
At the end of fiscal 2025 (December 31, 2025), Rapport Therapeutics had total assets of $512.4 million (up 62.7% from a year earlier), total liabilities of $27.8 million and shareholders' equity of $484.7 million. It held $490.5 million in cash and short-term investments against $11.5 million of debt, a net cash position of $479.1 million. Its current ratio was 26.17. In the latest quarter (ended June 30, 2026) total assets were $459.0 million and equity $422.9 million.
Related: RAPP income statement, RAPP cash flow statement, RAPP key metrics. See the RAPP stock overview for the latest quote and news.
RAPP balance sheet FAQ
What are Rapport Therapeutics's total assets?
Rapport Therapeutics reported total assets of $512.4 million at the end of fiscal 2025 (December 31, 2025), compared with $314.9 million a year earlier.
How much debt does Rapport Therapeutics have?
Rapport Therapeutics had $11.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.02.
How much cash does Rapport Therapeutics have?
Rapport Therapeutics held $490.5 million in cash and short-term investments at the end of fiscal 2025; with $11.5 million of debt that is net cash of $479.1 million.
What is Rapport Therapeutics's book value?
Rapport Therapeutics's shareholders' equity (book value) was $484.7 million at the end of fiscal 2025, or $10.32 per share.
What is Rapport Therapeutics's current ratio?
Rapport Therapeutics had current assets of $498.6 million and current liabilities of $19.0 million, a current ratio of 26.17 (it can cover its short-term obligations).